Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA goes union

This article was originally published in The Gray Sheet

Executive Summary

Review times should not be affected by the decision of FDA's non-supervisory employees in April to form two collective bargaining units, Susan Alpert, director of the agency's Office of Device Evaluation, says at a recent Food and Drug Law Institute meeting in Washington, D.C. As a result of the vote, FDA has entered into a memorandum of understanding with the National Treasury Employees Union. In addition to supervisors and administrative employees who handle personnel issues, the agreement excludes Public Health Service officers, of which 112 of FDA's 350 officers work in the Center for Devices and Radiological Health. A contract between FDA and NTEU has yet to be negotiated, according to agency staffers

You may also be interested in...



Respiratory Device Hand-off To FDA Dental Group Intended To Achieve Parity

Responsibility for reviewing respiratory device-related premarket submissions is expected to be transferred out of FDA's Division of Cardiovascular and Respiratory Devices (DCRD) to the Division of Dental, Infection Control and General Hospital Use Devices (DDIGD).

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT010328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel